FeLV and neoplasms in cats: a retrospective study in Grande Vitória

Brazilian journal of veterinary medicine · 2021

In plain language

This study reviewed test results from 388 cats seen at two veterinary institutions in Grande Vitória, Brazil. Tumors were reported in 34 of the 128 cats that tested positive only for FeLV. Incomplete records and conflicting data limit interpretation: this figure does not establish the risk of developing cancer or show that FeLV caused those tumors. The study also cannot determine how long the cats lived or whether any treatment was effective.

Scientific detail

Published in Brazilian journal of veterinary medicine in 2021, this study retrospectively analyzed immunoenzymatic test results from 388 cats attending two veterinary institutions in Grande Vitória, Espírito Santo, Brazil, between 2014 and 2016. It is a clinical observational series, not a controlled experiment. The reported results were 251 cats non-reactive for both viruses, 128 reactive only for FeLV, six reactive only for FIV, and three reactive for both. Medical records were recovered for 285 cats, and age was available for 244. The empirical claims included in the knowledge object carry evidence level C.

Neoplasms were reported in 34 of the 128 cats reactive only for FeLV, a frequency of 26.6% within that subgroup. Neoplasms documented among FeLV-reactive cats included lymphoma and acute lymphoid leukemia. This frequency does not establish incident cancer risk, causation, or a molecular mechanism. Among cats classified as infected only with FeLV, 25 of 128 reportedly died due to neoplasia before or during treatment. That denominator represents the entire subgroup, not just cats with neoplasms. Survival and disease-free intervals could not be specified; the observation establishes neither a survival distribution nor the effectiveness of any treatment.

The authors acknowledge inaccurate clinical information, sampling at only two institutions, and uncertainty about whether all attending cats were tested. These limitations constrain generalizability and interpretation of the frequencies, without quantifying the magnitude or direction of potential selection effects. Peripheral-blood PCR could not be performed, potentially leading to underestimation of infections; the authors also note that antigen testing may miss regressive FeLV infection. Incomplete medical record recovery and internal inconsistencies in aggregate neoplasm counts, including Discussion totals, and lymphoma subtype descriptions further limit interpretation. Procedures for diagnostic confirmation of neoplasms are not reported.

According to the authors, the genetic basis of the diversity of neoplasms induced by FIV, FeLV, and their recombinants remains poorly understood. The study did not investigate proviral integration sites, oncogene regulation, or tumor-specific viral recombination. Its findings provide descriptive clinical associations, not population-wide prevalence estimates, experimental evidence of insertional oncogenesis, causal estimates of cancer risk, or evidence of treatment efficacy.

What we know

In this retrospective series, with evidence level C, neoplasms were reported in 34 of 128 cats reactive only for FeLV (26.6%). It was also reported that 25 of the 128 cats in the subgroup classified as infected only with FeLV died due to neoplasia before or during treatment. These are descriptive observations from a two-institution sample, limited by incomplete records, inaccurate clinical information, testing limitations, and internal inconsistencies.

What we don't know

Survival and disease-free intervals are unavailable, and procedures for diagnostic confirmation of neoplasms are not reported. It is unclear whether all attending cats were tested, and potential selection effects were not quantified. Testing may have underestimated infections. The study does not establish population-wide prevalence, incident cancer risk, causation, or treatment efficacy. According to the authors, the genetic basis of the diversity of neoplasms induced by these viruses and their recombinants remains poorly understood; this study did not investigate those mechanisms.

Evidence

Provenance

This project does not diagnose or prescribe. Always consult your veterinarian.